ArticlePediatric research2026
Continuous transcutaneous CO
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient characteristics, vital signs and tcpCOFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypocapnia and hypercapnia are associated with significant morbidity in preterm infants. Continuous transcutaneous CO₂ (tCO₂) monitoring may reduce pCO₂ fluctuations and blood sampling requirements.
methodsA before-and-after study compared very low birth weight (VLBW) infants on high-frequency oscillatory ventilation (HFOV) before and after introducing tCO₂ monitoring. Primary outcomes were the incidences of hypercapnia (pCO₂ > 60 mmHg) and hypocapnia (pCO₂ < 40 mmHg) per day in HFOV. Secondary outcomes included the number of blood extractions per day and associations between tCO₂ monitoring and common neonatal morbidities.
resultsThe pre-tCO₂ group comprised 28 patients and the tCO₂ group 50 patients. Baseline characteristics were comparable. The tCO₂ group showed reductions in hypocapnia: 1 (IQR 0.35-2) vs. 0.15 (IQR 0-0.5), p < 0.01, and hypercapnia: 1.6 (IQR 0.87-2.6) vs. 0.5 (IQR 0.25-1), p < 0.01, as well as fewer blood samples per day: 5 (IQR 3.5-7) vs. 3 (IQR 2.5-4), p < 0.01. The tCO₂ group also showed a lower incidence of IVH, with no differences in mortality, transfusions, or other morbidities.
conclusionContinuous tCO₂ monitoring in VLBW infants on HFOV was associated with fewer episodes of hypo- and hypercapnia and reduced blood sampling. An association with lower IVH rates was observed; however, causality cannot be established. IMPACT: This study evaluates the impact of transcutaneous CO₂ monitoring using a before-and-after design, analyzing its association with blood gas stability and neonatal outcomes. The use of transcutaneous CO₂ monitoring was associated with fewer episodes of hypocapnia and hypercapnia, as well as a reduced need for frequent blood sampling. A lower incidence of intraventricular hemorrhage was also observed in the group with transcutaneous CO₂ monitoring. These findings support the potential value of integrating continuous transcutaneous CO₂ monitoring into neonatal intensive care practices to enhance patient safety and reduce complications related to CO₂ fluctuations.
Indexed as
Identifiers
41407889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.